These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36192074)

  • 1. And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
    Lau SCM; Ou SI
    J Thorac Oncol; 2022 Oct; 17(10):1144-1154. PubMed ID: 36192074
    [No Abstract]   [Full Text] [Related]  

  • 2. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Moik F; Riedl JM; Ay C
    Ann Oncol; 2024 Mar; 35(3):327. PubMed ID: 38092622
    [No Abstract]   [Full Text] [Related]  

  • 3. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    Nagasaka M; Zhu VW; Lim SM; Greco M; Wu F; Ou SI
    J Thorac Oncol; 2021 May; 16(5):740-763. PubMed ID: 33338652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
    Passaro A; Wang J; Shah S; Bauml JM; Campelo RG; Cho BC
    Ann Oncol; 2024 Mar; 35(3):328-329. PubMed ID: 38029840
    [No Abstract]   [Full Text] [Related]  

  • 5. Lazertinib: First Approval.
    Dhillon S
    Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
    Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
    J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer.
    Wang J; Wu L
    Expert Opin Pharmacother; 2022 Apr; 23(6):647-652. PubMed ID: 35272542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.
    Wang F; Zhou Q
    J Thorac Oncol; 2022 Apr; 17(4):481-486. PubMed ID: 35307103
    [No Abstract]   [Full Text] [Related]  

  • 9. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
    Shirley M; Keam SJ
    Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
    Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
    Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
    Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Furmonertinib: First Approval.
    Deeks ED
    Drugs; 2021 Oct; 81(15):1775-1780. PubMed ID: 34528187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
    Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
    Lu S; Dong X; Jian H; Chen J; Chen G; Sun Y; Ji Y; Wang Z; Shi J; Lu J; Chen S; Lv D; Zhang G; Liu C; Li J; Yu X; Lin Z; Yu Z; Wang Z; Cui J; Xu X; Fang J; Feng J; Xu Z; Ma R; Hu J; Yang N; Zhou X; Wu X; Hu C; Zhang Z; Lu Y; Hu Y; Jiang L; Wang Q; Guo R; Zhou J; Li B; Hu C; Tong W; Zhang H; Ma L; Chen Y; Jie Z; Yao Y; Zhang L; Jie W; Li W; Xiong J; Ye X; Duan J; Yang H; Sun M; Sun C; Wei H; Li C; Ali SM; Miller VA; Wu Q
    J Clin Oncol; 2022 Sep; 40(27):3162-3171. PubMed ID: 35580297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report.
    Deng Y; Yang C; Liu W; Cai S; Guo X
    Anticancer Drugs; 2022 Apr; 33(4):406-412. PubMed ID: 35266890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence.
    Ao L; Fang S; Zhang K; Gao Y; Cui J; Jia W; Shan Y; Zhang J; Wang G; Liu J; Zhou F
    J Exp Clin Cancer Res; 2022 May; 41(1):163. PubMed ID: 35501907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
    Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
    J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
    Park S; Ku BM; Jung HA; Sun JM; Ahn JS; Lee SH; Park K; Ahn MJ
    Cancer Res Treat; 2020 Oct; 52(4):1288-1290. PubMed ID: 32599977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
    Zhang Q; Liu H; Yang J
    Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.